Compare iShares Core High Dividend ETF (HDV) vs Summit Therapeutics Inc (SMMT) Price & Performance

HDV (iShares Core High Dividend ETF) trades at $28.82, up 1.91% with strong bullish technical signals from moving averages and oscillators. The ETF recently underwent a significant sector rebalancing, reducing healthcare exposure while increasing energy, staples, and utilities. Current dividend yield is approximately 3% with recent quarterly payouts between $0.06-$0.10 per share. Technical indicators show RSI at 77.74 suggesting potential overbought conditions near-term.

The outlook remains positive given the ETF's sector rotation toward defensive holdings and income focus, though concentration risk has increased with 62% in three sectors. Key risks include interest rate sensitivity and sector concentration, while opportunities lie in defensive positioning during market volatility. The 3% yield provides income appeal but requires monitoring of sector allocations.

Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.

The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.